Literature DB >> 19748811

Influence of hepatocyte nuclear factor 4alpha (HNF4alpha) gene variants on the risk of type 2 diabetes: a meta-analysis in 49,577 individuals.

Silvia Sookoian1, Carolina Gemma, Carlos J Pirola.   

Abstract

BACKGROUND: The nuclear receptor hepatocyte nuclear factor 4alpha (HNF4alpha) contributes to the regulation of a large fraction of liver and pancreatic islet transcriptomes. AIM: To evaluate the influence of HNF4alpha polymorphisms across the entire locus on the occurrence of type 2 diabetes (T2D) by means of a meta-analysis.
METHODS: We evaluated haplotype block structure of HNF4alpha variants owing to linkage disequilibrium (LD). From 1455 reports, we evaluated 21 observational studies.
RESULTS: Six haplotype blocks of LD were constructed with SNPs with r(2)>0.8; there were also 14 unlinked SNPs. Overall, we included 22,920 cases and 26.657 controls. Among 17 heterogeneous studies (21,881 cases and 24,915 controls), including 3 SNPs of P2 promoter region in block 1, we observed a significant association with T2D in fixed (OR 0.94, 95%CI: 0.905-0.975, p=0.001) and random (OR 0.988, 95%CI: 0.880-0.948, p=0.000012) model. Three homogeneous studies were evaluated in block 2 (2684 cases and 2059 controls), and a significant association with T2D was also observed: OR: 1.121, 95%CI 1.013-1.241, p=0.027. Three additional variants were associated with T2D: two intronic SNPs (rs4810424: OR: 1.080, 95%CI: 1.010-1.154, p<0.03 and rs3212183: OR: 0.843, 95%CI: 0.774-0.918, p<0.00009) and one missense variant (rs1800961: OR: 0.770, 95%CI: 0.595-0.995, p<0.05, 6562 cases and 6723 controls).
CONCLUSIONS: In addition to HNF4alpha variants in the promoter region, other SNPs may be involved on the occurrence of T2D.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19748811     DOI: 10.1016/j.ymgme.2009.08.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  8 in total

Review 1.  Metabolic syndrome: from the genetics to the pathophysiology.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

2.  Examination of Rare Variants in HNF4 α in European Americans with Type 2 Diabetes.

Authors:  Jacklyn N Hellwege; Pamela J Hicks; Nicholette D Palmer; Maggie C Y Ng; Barry I Freedman; Donald W Bowden
Journal:  J Diabetes Metab       Date:  2011-10-20

Review 3.  Epigenetics of insulin resistance: an emerging field in translational medicine.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Curr Diab Rep       Date:  2013-04       Impact factor: 4.810

4.  A role for coding functional variants in HNF4A in type 2 diabetes susceptibility.

Authors:  B Jafar-Mohammadi; C J Groves; A P Gjesing; B M Herrera; W Winckler; H M Stringham; A P Morris; T Lauritzen; A S F Doney; A D Morris; M N Weedon; A J Swift; J Kuusisto; M Laakso; D Altshuler; A T Hattersley; F S Collins; M Boehnke; T Hansen; O Pedersen; C N A Palmer; T M Frayling; A L Gloyn; M I McCarthy
Journal:  Diabetologia       Date:  2010-09-29       Impact factor: 10.122

5.  Nuclear receptor variants in liver disease.

Authors:  Roman Müllenbach; Susanne N Weber; Frank Lammert
Journal:  J Lipids       Date:  2011-12-21

6.  Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.

Authors:  Kathrin Klein; Stefan Winter; Miia Turpeinen; Matthias Schwab; Ulrich M Zanger
Journal:  Front Pharmacol       Date:  2010-11-02       Impact factor: 5.810

7.  Hepatocyte nuclear factor 4 alpha polymorphisms and the metabolic syndrome in French-Canadian youth.

Authors:  Valérie Marcil; Devendra Amre; Ernest G Seidman; François Boudreau; Fernand P Gendron; Daniel Ménard; Jean François Beaulieu; Daniel Sinnett; Marie Lambert; Emile Levy
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

8.  Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.